Quick Take
- DITTO seed round raised $6 Mn (Rs 57.9 Cr), led by FoodLabs with Eka Ventures returning.
- The 2024-founded UK startup has grown its community to 300,000 members in 18 months.
- Funds back its Cycle Supplement, plus three new clinical trials over the next 12 months.
In This Article
The DITTO seed round has closed at $6 Mn (Rs 57.9 Cr), led by FoodLabs, with existing backer Eka Ventures returning, on July 28, 2026. DITTO is a women-led menstrual health startup based in the United Kingdom.
The company builds evidence-based supplements for PMS (premenstrual syndrome) and PMDD (premenstrual dysphoric disorder), two conditions tied to the menstrual cycle. Eka Ventures first backed DITTO by leading its £1.35 Mn pre-seed round in August 2025, and has now doubled down at the seed stage. Across both disclosed rounds, DITTO has raised about $7.7 Mn to date. The raise lands as femtech (female health technology) draws fresh investor attention worldwide, including in India.
StartupFeed Insight
The DITTO seed round marks a shift StartupFeed sees clearly: menstrual health is moving from anecdote to clinical proof. DITTO reports 88% of trial participants saw lower symptom severity, and that number, not marketing, is what pulled a repeat cheque from Eka Ventures. Indian femtech founders should watch closely, because the same clinical-evidence bar will soon decide which women’s health brands raise capital here. Expect at least one India-based menstrual health startup to announce a research-led supplement raise above Rs 40 Cr before mid-2027, as investors reward data over reach. By Harshvardhan Jain.
DITTO Seed Round: The Deal Breakdown
The DITTO seed round is a $6 Mn (Rs 57.9 Cr) raise led by FoodLabs, a European venture firm, with Eka Ventures participating again. The table below sets out the key deal facts, as confirmed by the company and its lead investors.
| Metric | Detail | Notes |
|---|---|---|
| Total Raise | $6 Mn (Rs 57.9 Cr) | Seed round |
| Lead Investor | FoodLabs | New lead backer |
| Returning Investor | Eka Ventures | Led the pre-seed |
| Previous Round | £1.35 Mn pre-seed | August 2025 |
| Cumulative Raised | About $7.7 Mn | Both disclosed rounds |
| Announcement Date | July 28, 2026 | Per company and investors |
The stand-out detail is investor loyalty: Eka Ventures led the pre-seed and returned for the seed, a strong signal of conviction in a young brand.
About DITTO
DITTO is a UK menstrual health startup founded in 2024 by neuroscientist and nutrition scientist Alice van der Schoot, alongside former L’Oreal brand director Adam Kugler. Based in the United Kingdom, it sells science-led supplements, led by its Cycle Supplement, that target PMS and PMDD symptoms. The team has grown to 15 people. Backers include FoodLabs and Eka Ventures.
How will DITTO use the funds?
DITTO will use the seed capital to expand its supplement range and deepen its clinical research. Founder Alice van der Schoot plans three more clinical trials and five published papers over the next 12 months. A key study is a systematic review of the overlap between PMDD and ADHD (attention deficit hyperactivity disorder).
“In the market of menstrual health, clinical evidence is becoming the price of entry, and the first company to set that standard is the one everyone else gets measured against,” said Flo Breiner, operating partner, FoodLabs.
The plan puts research spending at the centre. That focus matters in a sector where many brands lead with lifestyle claims rather than trial data. DITTO is betting that proof will win both customers and doctors, and its published clinical results back that bet.
Why did FoodLabs back DITTO?
FoodLabs backed DITTO because clinical evidence is becoming the entry standard in menstrual health, and DITTO set that bar early. The firm sees first-mover advantage in a brand that rivals will be measured against. DITTO’s community has grown to 300,000 members in 18 months, up from 116,000 at its pre-seed.
“The science earns trust, and trust is what scales a brand. That combination is hard to find, and it’s precisely what we want to back,” said Camilla Dolan, general partner, Eka Ventures.
That logic explains why a pre-seed lead came back for more. DITTO’s flagship Cycle Supplement was co-developed with female scientists, including gynaecologist Dr Anita Mitra, adding medical credibility that lowers the usual risk in early consumer health bets.
How does DITTO compare in femtech?
DITTO sits in a crowded femtech field, but few rivals lead with the same clinical-first pitch. The global PMS and menstrual health supplements market was valued at $22.6 Bn in 2022 and is projected to reach $35 Bn by 2030, according to Grand View Research. The comparison below shows where DITTO stands.
| Company | Focus | Model |
|---|---|---|
| DITTO | PMS and PMDD supplements | Clinical-trial-led supplements |
| Semaine Health | PMS and menopause supplements | Supplement brand, undisclosed raise |
| Flo / Clue | Period tracking | Software, not supplements |
What sets DITTO apart is its refusal to make claims without trials, a stance that turns its research into a moat rivals cannot copy quickly.
What’s Next
DITTO’s next milestone is delivering three clinical trials and five papers within 12 months, including its PMDD-ADHD review. Success there could open doctor referrals and new markets, potentially including demand-heavy regions like India. Will clinical proof become the price of entry for every women’s health brand chasing venture money?
Frequently Asked Questions
Have a tip? Write to us at editorial@startupfeed.in.
